Dementia with Lewy bodies (DLB), the second most common type of dementia, requires a multifactorial approach to reduce symptoms.

The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s ...

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a ...

The trial failed to achieve statistical significance in its goal of improved MCCB neurocognitive composite scores.

A 19-year-old woman with a history of depression and anxiety symptoms was admitted to the hospital because of seizure, ...

VINE senior center has received a $10,000 grant from the Mankato Clinic Foundation to support four new programs designed to ...

Acute extrapyramidal side effects after using metoclopramide are harmless and reversible, but undoubtedly a dramatic and unpleasant experience for patients. It is essential to be aware that the ...

The Penn Highlands Healthcare Parkinson’s Support Group will hold its next meeting on Wednesday, Aug. 13 from 2 to 3:30 p.m. at the Parkside Community Center, located at ...

Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...

Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...